BioCentury

Since its inception in 1993, BioCentury, Inc. has earned a global reputation as a top source of valuable insights, analysis, and data for those in the biotechnology and pharmaceutical sectors, as well as investors, academic institutions, and government entities. They focus on key strategic issues that are vital for creating, growing, and maintaining life science companies. BioCentury utilizes a comprehensive multimedia approach that encompasses publications, videos, online data tools, and conferences. This allows them to offer their audience reliable and current information on various topics, including corporate strategies, partnerships, emerging technologies, clinical research, public policies, and financial markets. The editorial and research teams at BioCentury consist of well-respected editors and writers in both business and science. The company is led by a management team with diverse expertise, including international business, publishing, finance, and experience in the biotech and pharmaceutical fields. BioCentury is based in Redwood City, California, with additional offices located in Washington, D.C.; Chicago; and London.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#496262

United States

#216731

Health/Biotechnology and Pharmaceuticals

#171

Traffic sources

Monthly visitors

Articles

Beech: Treating pregnancy complications without affecting the fetus

1 day ago | biocentury.com | Danielle Golovin

ARTICLE | Emerging Company ProfileSwitzerland-based newco has new grant from Gates Foundation to advance a preeclampsia treatment that doesn’t cross the placenta By Danielle Golovin, Senior Biopharma AnalystFor decades, drug development for pregnancy complications has been paralyzed by fear of harming the fetus — leaving physicians with few safe options to treat even life-threatening maternal conditions.
Science Spotlight: Targets to enhance CAR-NK cell therapies

3 days ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationBioCentury’s roundup of translational innovations also includes Recode’s multi-organ targeted LNPs and tau-vulnerable neurons in Alzheimer’s By Danielle Golovin, Senior Biopharma AnalystTwo recent papers describe intracellular checkpoints that limit NK cell antitumor activity, suggesting targets to enhance the efficacy of CAR-NK cell therapies.
Fibromyalgia drug nearing approval after a 16-year lull

4 days ago | biocentury.com | Danielle Golovin

ARTICLE | Product DevelopmentAs Tonix awaits FDA decision, Axsome receives refuse-to-file letter By Danielle Golovin, Senior Biopharma AnalystAfter 16 years without a new approval, fibromyalgia patients may be on the cusp of getting a therapy that improves pain, sleep and fatigue — the triad of symptoms that define the chronic condition.
Fritz Bittenbender: guiding BIO through an America First era

1 week ago | biocentury.com | Steve Usdin

ARTICLE | Politics, Policy & LawBIO’s new board chair on MFN pricing, political realism, and why the industry can’t just say no anymore By Steve Usdin, Washington EditorFritz Bittenbender is taking on the job of BIO board chair at time when the biotech industry is facing public policy challenges across the value chain, from threats to the NIH funding of biomedical research that fuels early stage companies to the specter of international reference pricing crushing profitability.
CHMP recommends five new drugs

1 week ago | biocentury.com | Meredith Durkin Wolfe

DATA GRAPHICS | Data ByteFour of the five are already approved in the U.S. By Meredith Durkin Wolfe, Director of ResearchEMA’s CHMP recommended five new products for approval at its June meeting. Four are already approved in the U.S. for the same indications. The fifth — allogenic stem cell therapy Zemcelpro from Excellthera Inc. — has not yet been submitted to FDA.
Amarin, Merck alum Karim Mikhail emerges as possible head of FDA’s CDER

1 week ago | biocentury.com | Steve Usdin

ARTICLE | Politics, Policy & LawThe former Amarin CEO and Merck executive is serving as an adviser to Commissioner Makary By Steve Usdin, Washington EditorFDA Commissioner Marty Makary has hired former pharmaceutical executive Karim Mikhail as a senior adviser and is considering appointing him as director of the Center for Drug Evaluation and Research, current and former FDA officials told BioCentury.
Myostatin inhibition gets further PoC for lean mass preservation in obesity

1 week ago | biocentury.com | Stephen Hansen

ARTICLE | Product DevelopmentScholar Rock shows 55% lean mass preservation for apitegromab vs. Zepbound in Phase II readout By Stephen Hansen, Director of Biopharma IntelligenceTwo recent Phase II studies have established proof of concept that myostatin inhibitors can substantially improve the quality of weight loss, without adding any notable toxicity, when combined with marketed obesity therapies. They also set the bar for the upcoming readout of Lilly’s activin antagonist bimagrumab.
Makary’s priority pathway charts new territory, linking regulatory decisions to national security

1 week ago | biocentury.com | Steve Usdin

ARTICLE | Politics, Policy & LawIndustry enthusiastic about streamlining reviews, concerned the program could become politicized By Steve Usdin, Washington Editor Biopharma executives applauded a pilot priority review pathway announced by FDA Commissioner Marty Makary Tuesday, anticipating streamlined reviews of innovative drugs, but some industry leaders, FDA officials and patient advocates privately expressed concerns.
A $1B bet on gene editing could bolster Lilly’s CV pipeline

1 week ago | biocentury.com | Stephen Hansen

ARTICLE | DealsVerve takeout adds base editing platform with big CV market opportunities By Stephen Hansen, Director of Biopharma Intelligence and Lauren Martz, Executive Director of Biopharma IntelligenceLilly is using its obesity cash pile to increase the optionality for its fledgling cardiovascular pipeline through a deal that gives the pharma full control of a clinical-stage modality that it already had rights to in what is expected to be a highly competitive space.
A $1B bet on gene editing could bolster Lilly’s CV arsenal

1 week ago | biocentury.com | Stephen Hansen

ARTICLE | DealsVerve takeout adds base editing platform with big CV market opportunities By Stephen Hansen, Director of Biopharma Intelligence and Lauren Martz, Executive Director of Biopharma IntelligenceLilly is using its obesity cash pile to increase the optionality for its fledgling cardiovascular pipeline through a deal that gives the pharma full control of a clinical-stage modality that it already had rights to in what is expected to be a highly competitive space.